Skip to main content
SpringerLink
Log in
Book cover

Management of Localized Pancreatic Cancer pp 105–112Cite as

Treatment Sequencing for Locally Advanced Pancreatic Cancer

  • Chapter
  • First Online:

  • 431 Accesses

Abstract

Treatment sequencing for locally advanced pancreatic cancer (LAPC) described in this chapter utilizes a logical trimodal approach, which capitalizes on the strengths of each treatment modality. Four to six months minimum of chemotherapy treats micrometastatic disease and selects out patients who are not appropriate candidates for local therapies. Radiation then sterilizes margins and lymph nodes and treats the perineurium known to commonly be involved in locally advanced cases. Surgical resection then removes the tumor and involved vasculature, not only enhancing local disease control but also giving patients the best overall chance for prolonged survival and potential cure. Herein, we describe the rationale and results of this approach to the treatment of LAPC.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148:348–61.

    Article  Google Scholar 

  2. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.

    Article  CAS  Google Scholar 

  3. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24:3946–52.

    Article  CAS  Google Scholar 

  4. Boeck S, Hoehler T, Seipelt G, Mahlberg R, Wein A, Hochhaus A, Boeck HP, Schmid B, Kettner E, Stauch M, et al. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem)versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Ann Oncol. 2008;19:340–7.

    Article  CAS  Google Scholar 

  5. Fine RL, Fogelman DR, Schreibman SM, Desai M, Sherman W, Strauss J, Guba S, Andrade R, Chabot J. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol. 2008;61:167–75.

    Article  CAS  Google Scholar 

  6. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.

    Article  Google Scholar 

  7. Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J, Teixeira L, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015;107:dju413.

    Article  Google Scholar 

  8. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.

    Article  CAS  Google Scholar 

  9. Loehrer P, Powell ME, Cardenes HR, et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized unresectable pancreatic cancer: E4201. J Clin Oncol. 2008;26(Suppl):abstract 4506.

    Article  Google Scholar 

  10. Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013;14:317–26.

    Article  CAS  Google Scholar 

  11. Krishna S, Chadha AS, Suh Y, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidation chemoradiation. Int J Radiat Oncol Biol Phys. 2016;94(4):755–65.

    Article  Google Scholar 

  12. Chung SY, Chang JS, Lee BM, et al. Dose escalation in locally advanced pancreatic cancer patients receiving chemoradiotherapy. Radiother Oncol. 2017;123:438–45.

    Article  Google Scholar 

  13. De Geus SWL, Eskander MF, Kasumova GG, et al. Stereotactic body radiotherapy for unresected pancreatic cancer: a nationwide review. Cancer. 2017;123(21):4158–67.

    Article  Google Scholar 

  14. Rosati LM, Herman JM. Role of stereotactic body radiotherapy in treatment of elderly and poor performance patients with pancreatic cancer. J Oncol Pract. 2017;13(3):157–66.

    Article  Google Scholar 

  15. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27:1806–13.

    Article  CAS  Google Scholar 

  16. Gutt R, Liauw SL, Weichselbaum RR. The role of radiotherapy in locally advanced pancreatic carcinoma. Nat Rev Gastroenterol Hepatol. 2010;7:437–47.

    Article  Google Scholar 

  17. Evans DB, George B, Tsai S. Non-metastatic pancreatic cancer: resectable, borderline resectable, and locally advanced-definitions of increasing importance for the optimal delivery of multimodality therapy. Ann Surg Oncol. 2015;22(11):3409–13.

    Article  Google Scholar 

  18. Kang CM, Chung YE, Park JY, et al. Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer. J Gastrointest Surg. 2012;16(3):509–17.

    Article  Google Scholar 

  19. Pilgrim C, Tsai S, Ritch P, George B, Evans DB, Christians KK. Arterial resection at the time of pancreatectomy for cancer. Surgery. 2014;155(5):919–26.

    Article  Google Scholar 

  20. Younan G, Tsa S, Evans DB, Christians KK. Techniques of vascular resection and reconstruction. Surg Clin N Am. 2016;96:1351–70.

    Article  Google Scholar 

  21. Chatzizacharias N, Tsai S, Griffin M, Tolat P, Ritch P, George B, Barnes C, Aldakkak M, Khan AH, Hall W, Erickson B, Evans DB, Christians KK. Locally advanced pancreatic cancer: staging and goals of therapy. Surgery. 2018;pii: S0039-6060(17):30633–5. https://doi.org/10.1016/j.surg.2017.09.012.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Department of Surgery, The Medical College of Wisconsin, Milwaukee, WI, USA

    Kathleen K. Christians

  2. Department of Radiation Oncology, The Medical College of Wisconsin, Milwaukee, WI, USA

    Beth A. Erickson

Authors
  1. Kathleen K. Christians
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Beth A. Erickson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kathleen K. Christians .

Editor information

Editors and Affiliations

  1. Division of Surgical Oncology, Department of Surgery, The Medical College of Wisconsin, Milwaukee, WI, USA

    Susan Tsai

  2. Division of Medical Oncology, Department of Medicine, The Medical College of Wisconsin, Milwaukee, WI, USA

    Paul S. Ritch

  3. Department of Radiation Oncology, The Medical College of Wisconsin, Milwaukee, WI, USA

    Beth A. Erickson

  4. Department of Surgery, The Medical College of Wisconsin, Milwaukee, WI, USA

    Douglas B. Evans

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Christians, K.K., Erickson, B.A. (2019). Treatment Sequencing for Locally Advanced Pancreatic Cancer. In: Tsai, S., Ritch, P., Erickson, B., Evans, D. (eds) Management of Localized Pancreatic Cancer . Springer, Cham. https://doi.org/10.1007/978-3-319-98944-0_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-98944-0_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-98943-3

  • Online ISBN: 978-3-319-98944-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation